This Wednesday, High Court Judge Michael Quinn approved the scheme of arrangement submitted by examiner Michael McAteer of Grant Thornton to put Mallinckrodt PLC back on its feet.  The Irish footprint of the US-focused pharmaceutical group includes a manufacturing and R&D plant in the Dublin suburb of Blanchardstown, which makes its flagship drug Acthar and employs 110 people. Irish subsidiaries also make use of this country’s favourable tax regime to own multi-billion-dollar intellectual property covering Acthar and other medical innovations. But these units were not the target of the latest insolvency proceedings. Instead, Irish-registered Mallinckrodt PLC is the ultimate parent…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €100.

Subscribe

Cancel anytime.

Are you already a member? .